Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The Lancet Oncology

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(14)71205-7PMID 25601341
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

  2015cited by this paper
• Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

  2015cited by this paper
• Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

  2014cited by this paper
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014cited by this paper
• Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials.

  2014cited by this paper
• Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

  2014cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D).

  2013cited by this paper
• Alpha emitter radium-223 and survival in metastatic prostate cancer.

  2013cited by this paper
• Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.

  2013cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary

  2013cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

  2012cited by this paper
• Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a Us managed care population

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• A population-based study of prostate cancer chemotherapy.

  2011cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Estimating a treatment effect in survival studies in which patients switch treatment

  2002cited by this paper
• The Statistical Analysis of Failure Time Data

  1980cited by this paper

• Radiographic progression-free survival as a surrogate endpoint for overall survival in first-line ARPi naïve metastatic castration-resistant prostate cancer

  2026cites this paper
• Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany.

  2026cites this paper
• Impact of Abiraterone Therapeutic Drug Monitoring on Cortisol as a Surrogate Biomarker of CYP17 Inhibition in Metastatic Prostate Cancer Treatment.

  2026cites this paper
• Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection—Results of the MEET-URO 22 Study

  2026influential citation
• MiRNA based liquid biopsy for castration-resistant prostate cancer diagnostics.

  2026cites this paper
• Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

  2026cites this paper
• Bibliometric Analysis of Quality of Life in Patients with Prostate Cancer

  2026cites this paper
• Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro).

  2026cites this paper
• Abiraterone-Associated Renal Damage in Patients with Advanced Prostate Cancer as a Risk Factor for Mortality and Chronic Kidney Disease

  2025cites this paper
• Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer

  2025cites this paper
• Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment

  2025influential citation
• PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis

  2025cites this paper
• Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.

  2025cites this paper
• Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer.

  2025cites this paper
• Clinical value of emerging peripheral blood protein biomarkers in prostate cancer (Review)

  2025cites this paper
• Circadian rhythm-related miR-6883-5p suppresses enzalutamide-resistant prostate cancer

  2025cites this paper
• The contemporary management of prostate cancer

  2025cites this paper
• A Prospective, Multicenter Study on the Clinical Effectiveness and Safety of Abiraterone Plus Prednisone in Metastatic Hormone-Sensitive Prostate Cancer in Korea: Real-World Data Analysis

  2025cites this paper
• Combination of clinicopathological and MRI based radiomics features in predicting homologous recombination repair genes mutations in prostate cancer.

  2025cites this paper
• Drug-like molecules targeting androgen receptor's allosteric binding sites selected by augmented AI and high-throughput screening as antitumor agents against prostate cancer.

  2025cites this paper
• Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial.

  2025cites this paper
• Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.

  2025cites this paper
• Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2025cites this paper
• Automated imaging as an adjunct to serum and clinical biomarkers: a new validated prediction tool for metastatic castration-resistant prostate cancer.

  2025cites this paper
• Two Cases of Metastatic Castration‐Resistant Prostate Cancer With Long‐Term Survival Treated With Abiraterone

  2025influential citation
• Impact of CYP17A1 Gene Polymorphisms on Abiraterone Efficacy in Prostate Cancer: A Systematic Review

  2025cites this paper
• Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial

  2025cites this paper
• CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors

  2025cites this paper
• Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan

  2025cites this paper
• Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancer

  2025cites this paper
• Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences

  2025cites this paper
• Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada

  2025cites this paper
• Real-world effectiveness of novel hormonal agents and docetaxel in patients with prostate cancer: A head-to-head comparison

  2025cites this paper
• A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate‐Resistant Prostate Cancer (TRICREST)

  2025cites this paper
• Patient characteristics, treatment patterns, and survival outcomes in patients with castration-resistant prostate cancer: results from the J-CaP registry

  2025cites this paper
• Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC).

  2025cites this paper
• Thromboembolic Events in Castration‐Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors

  2025cites this paper
• A Multiparametric MRI and Baseline-Clinical-Feature-Based Dense Multimodal Fusion Artificial Intelligence (MFAI) Model to Predict Castration-Resistant Prostate Cancer Progression

  2025cites this paper
• Packing the Punch: Current and Emerging Treatment Strategies in Metastatic Castration-Sensitive Prostate Cancer

  2025cites this paper
• Osteosclerotic changes on computed tomography predict disease progression and poor survival in prostate cancer with osteoblastic metastases

  2025cites this paper
• Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

  2025cites this paper
• Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer.

  2025cites this paper
• Management of Metastatic Prostate Cancer

  2025cites this paper
• Comparative neurological safety of novel hormonal therapies in advanced prostate cancer: a Bayesian network meta-analysis of randomized trials

  2025cites this paper
• Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis

  2025cites this paper
• Adverse events associated with Lutetium-177-PSMA-617 (Pluvicto®) in advanced prostate cancer: a disproportionality analysis based on the fda’s adverse event reporting system (FAERS)

  2025cites this paper
• Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.

  2025cites this paper
• Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• Real-World Treatment Patterns and Survival in Metastatic Castration-resistant Prostate Cancer: A Systematic Review of Observational Studies.

  2025cites this paper
• mpMRI-based interpretable machine learning model for predicting castration-resistant prostate cancer risk.

  2025cites this paper
• Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification.

  2025cites this paper
• Bone metastases from endocrine cancer: advances in diagnosis, treatment, and prevention

  2025cites this paper
• Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC

  2025cites this paper
• Cabazitaxel versus abiraterone or enzalutamide for metastatic castration-resistant prostate cancer following docetaxel failure: a systematic review and meta-analysis

  2025cites this paper
• Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy

  2025cites this paper
• Treatment switching between Enzalutamide and Abiraterone Acetate and time to oral opioid initiation in castration-resistant prostate cancer patients.

  2025cites this paper
• The impact of dysregulation SUMOylation on prostate cancer

  2025cites this paper
• Voluntary Exercise Attenuates Tumor Growth in a Preclinical Model of Castration-Resistant Prostate Cancer.

  2025cites this paper
• Current Status of Sequential Treatment for Castration-resistant Prostate Cancer: A Retrospective Analysis

  2025cites this paper
• Considerable decline in prostate cancer mortality in Nordic countries after 2000

  2025cites this paper
• Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study

  2025influential citation
• PROTAC technology for prostate cancer treatment.

  2025cites this paper
• The role of SOX transcription factors in prostate cancer: Focusing on SOX2

  2025cites this paper
• A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia

  2025cites this paper
• Prognostic Role of Prostate‐specific Antigen Isoforms and Their Early Kinetics in Patients With Metastatic Castration‐resistant Prostate Cancer Receiving New Generation Androgen Receptor Targeted Agents

  2025cites this paper
• Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries

  2025cites this paper
• The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: a narrative review.

  2025cites this paper
• Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges

  2025cites this paper
• Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration‐Resistant Prostate Cancer: PROpel Subset Analysis

  2025cites this paper
• The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo

  2025cites this paper
• Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial

  2025cites this paper
• Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration‐Resistant Prostate Cancer Patients: A Sub‐Analysis From the ENABLE Study

  2025cites this paper
• Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer.

  2025cites this paper
• Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review

  2025cites this paper
• Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC.

  2025cites this paper
• Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study.

  2025cites this paper
• Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.

  2025cites this paper
• 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update).

  2025cites this paper
• Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience.

  2025cites this paper
• Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer

  2025cites this paper
• Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial.

  2025cites this paper
• Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors

  2025cites this paper
• Comparative Effectiveness of First‐Line Treatments for Castration‐Resistant Prostate Cancer: A Large‐Scale Retrospective Study in Japan

  2025cites this paper
• Diagnostic value of dual-tracer PET/CT with [18F]FDG and PSMA ligands in prostate cancer: an updated systematic review

  2025cites this paper
• Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

  2025cites this paper
• Efficacy and safety of first-line treatments for metastatic castration-resistant prostate cancer based on phase II and III randomized controlled trials: A PROSTA-MAP systematic review and network meta-analysis

  2025cites this paper
• 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

  2025cites this paper
• Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches

  2025cites this paper
• The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials

  2025cites this paper
• Chinese medicines as therapeutic options for treating prostate cancer: Therapeutic effects and underlying mechanisms.

  2025cites this paper
• Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site‐Directed Therapy for Castration‐Resistant Prostate Cancer

  2025cites this paper
• Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer.

  2025cites this paper
• The Prognostic Roles of Systemic Inflammatory Markers Before Abiraterone or Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer

  2025cites this paper
• Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research

  2025cites this paper
• Real-world treatment patterns and survival outcomes in patients with metastatic castration-resistant prostate cancer in France: lessons from the prospective OPALE study.

  2025cites this paper
• Safety and Efficacy of Niraparib in Metastatic Castration-resistant Prostate Cancer: Systematic Review and Meta-analysis

  2024cites this paper
• Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis

  2024cites this paper
• A 13-years pharmacovigilance analysis of novel hormonal agents in prostate cancer using the FDA adverse event reporting system database.

  2024cites this paper
• Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer.

  2024cites this paper
• Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.

  2024cites this paper